Caligan Partners LP - 28 Apr 2022 Form 4 Insider Report for STANDARD BIOTOOLS INC. (LAB)

Role
10%+ Owner
Signature
Caligan Partners LP, By: /s/ David Edward Johnson, Partner
Issuer symbol
LAB
Transactions as of
28 Apr 2022
Net transactions value
+$1,075,574
Form type
4
Filing time
02 May 2022, 19:44:18 UTC
Previous filing
18 Apr 2022
Next filing
10 May 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LAB Common Stock, $0.001 par value per share ("Common Stock") Purchase $66,240 +27,600 +0.3% $2.40 9,112,438 28 Apr 2022 See footnote F1, F2, F5
transaction LAB Common Stock Purchase $658,084 +247,400 +2.7% $2.66 9,359,838 29 Apr 2022 See footnote F2, F3, F5
transaction LAB Common Stock Purchase $351,250 +125,000 +1.3% $2.81 9,484,838 02 May 2022 See footnote F2, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Price is the volume weighted average selling price of all sales by Caligan Partners LP ("Caligan") and David Johnson (together with Caligan, the "Reporting Persons") on the transaction date for prices ranging from $2.37 to $2.44.
F2 The securities reported herein are held by an affiliated fund and managed account of Caligan. David Johnson is a Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan.
F3 Price is the volume weighted average selling price of all sales by the Reporting Persons on the transaction date for prices ranging from $2.57 to $2.70.
F4 Price is the volume weighted average selling price of all sales by the Reporting Persons on the transaction date for prices ranging from $ 2.71 to $2.89.
F5 The Reporting Persons hereby undertake to provide upon request of the staff of the Securities and Exchange Commission full information regarding the number of shares sold at each separate price.

Remarks:

The Persons disclaim beneficial ownership in the securities reported on this Form 4 except to the extent of his or its pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that any of the Reporting Persons are the beneficial owner of such securities for purposes of Section 16 or for any other purpose.